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Whereas it may be difficult systematically to follow up cohorts of
women who have had amniocentesis under specified conditions,
this objective could be achieved if readily accessible information
systems were in place covering amniocentesis use in the population,
and congenital anomalies. The coexistence of these two information
systems would also (and as their main objective) allow the evaluation
of the impact of prenatal screening in the population. It is
unfortunate that, in most areas of Europe, either one or both of these
information systems is lacking.
Other members of the EUROCAT Working Group are: Dr S. Shawky
(Brussels), Dr M. C. Comel (Groningen), Dr F. Lys (Hainaut), Dr S. Ayme
(Marseille), Dr E. Garne (Odense), Dr J. Goujard (Paris), Prof. N. Nevin
(Belfast), Dr A. Radic (Dublin), Prof. C. Stoll (Strasbourg), Dr D. Stone
(Glasgow), Prof. I. Svel (Zagreb), Ms E. White (Liverpool), and Prof. M. F.
Lechat (project leader, Brussels).
EUROCAT Central Registry,
Department of Epidemiology,
Ecole de Sant&eacute; Publique, EPID 30.34,
1200 Brussels, Belgium
H. DOLK,
for EUROCAT Working Group
1. Moorman-Voestermans CGM, Heig HA, Vos A. Jejunal atresia in twins. J Pediatr
Surg 1990; 25: 638-39.
2. Television broadcast in the Netherlands, reporting findings of Amsterdam group in ref
1, July 11, 1990.
3. Wesselius J. Methyleenblauw blijft verdacht (reporting ref 1). Nieuwsblad
Gezondheidzorg Nov 20, 1990.
4. Nicolini U, Monni G. Intestinal obstruction in babies exposed in utero to methylene
blue. Lancet 1990; 336: 1258.
5. EUROCAT Working Group. EUROCAT report 4: surveillance of congenital
anomalies, 1980-88. Catholic University of Louvain, Brussels: Department of
Epidemiology, 1991.
Sedative and hypnotic withdrawal states in
inpatients
SIR,-We read with interest Dr Moss’ letter (Aug 31, p 575)
reporting on sedative-hypnotic drug withdrawal states in inpatients
as a result of house staff being warned against the routine
prescription of benzodiazepines for night-time sedation. We have
done a prospective study of the part played by hospital admission on
the introduction and withdrawal of hypnotics and tranquillisers,
and would like to comment on Moss’ letter.
119 consecutive patients admitted to an internal medicine
department were studied. 31% of the patients were receiving a
hypnotic or tranquilliser before admission. Although this figure
slightly increased during the period in hospital (35%), 14 patients
had hypnotics or tranquillisers withdrawn. 31 additional
withdrawals occurred at discharge; among the 42 patients receiving
these drugs while in hospital only 11 were prescribed such
medication at discharge. It can be expected that some of those who
had drugs withdrawn will subsequently resume this therapy.
However, our study does show that drug withdrawal is especially
common at discharge. House-staff need to be aware of the dangers
of iatrogenic withdrawal arising not only during admission but also
after discharge.
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Sexual disturbances during omeprazole
therapy
SiR,--0meprazole is the first of a new class of drugs that inhibit
gastric secretion by altering the activity of H+/K+-ATPase.1 1
Although it has a minor inhibitory effect on the synthesis of adrenal
steroids, it has no important clinical effects on endocrine or sexual
function.2
A 77-year-old man was treated with omeprazole 20 mg once daily
for oesophagitis induced by tiaprofenic acid, diagnosed
endoscopically. This patient also used transdermal glyceryl
trinitrate for angina pectoris for many years. During omeprazole
treatment painful noctural erections developed, without an increase
in libido; these erections disappeared when the drug was stopped 6
weeks later. Treatment was resumed intermittently by the patient
because of recurrent and irregular epigastric pain. After each tablet,
pain regressed for 36 h but painful erections recurred during this
same period. Since abdominal pain had disappeared with this
irregular treatment over 2 months, omeprazole was stopped and no
more sexual disturbances appeared. He had no history of perineal
injury or intracavernosal injections. There was no inflammation of
penis or traces of injections. Blood counts were normal.
Glyceryl trinitrate, a potent vasodilator, was excluded as a
possible cause because it was continued after sexual disorders
disappeared. Although omeprazole does not seem to affect sex-
hormone metabolism, gynaecomastia has been reported in one
man.3 Since erections appeared in our patient during omeprazole
treatment and recurred after each tablet, a causal relation is possible;
furthermore, erections persisted for 36 h, the time during which
omeprazole inhibitis acid secretion.4
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Pharmacotoxic psychosis after memantine
in Parkinson’s disease
SIR,-Dopamine has proved in animals to be of less importance
in the regulation of psychomotor functions than previously
believed. A clear behavioural activation can be produced in rodents
after suppression of glutamatergic neurotransmission, even in the
absence of brain dopamine. It has therefore been proposed that
N-methyl-D-aspartate (NMDA) antagonists are potentially useful
as antiparkinsonian drugs 2 Antiglutamatergic drugs for the
treatment of Parkinson’s disease are the non-competitive NMDA
receptor antagonists amantadine and memantine.3.4 The
antiparkinsonian activity of memantine may be explained by its
action at the NMDA receptor,4 since the K1 value of memantine is
below the brain concentration achieved in the treatment of
Parkinson’s disease.s Reduced activity within glutamatergic
pathways might be an important factor in the pathophysiology of
schizophrenia.’ The therapeutic use of NMDA antagonists in
Parkinson’s disease may therefore have the potential to cause
psychotic side-effects. We have examined the motor performance
and the occurrence of pharmacotoxic psychosis after administration
of memantine in patients with Parkinson’s disease.
Four patients with Parkinson’s disease received 10-30 mg
memantine daily for up to six weeks, in addition to their usual
medication, with a view to improving their motor performance
(table). Improvement in motor symptoms was rated according to
Webster (modified sealer. The degree of pharmacotoxic psychosis
was rated according to Moskovitz.8 Only one patient showed a mild
improvement in motor symptoms after memantine treatment for
three weeks. In two of the other three, however, memantine
produced pharmacotoxic psychosis.
These results suggest that memantine in doses producing little or
no antiparkinsonian effects is likely to cause pharmacotoxic
psychosis. Amantadine is known to have dose-dependent anti-
akinetic effects in parkinsonian patients and psychosis is a frequent
adverse reaction.9 Although these NMDA antagonists show some
antiparkinsonian activity at sufficiently high doses, the risk of
psychotic side-effects is considerable. In Parkinson’s disease there
are few data confirming a disturbance of glutamatergic function in
limbic or cortical areas and supporting a glutamatergic hypothesis of
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pharmacotoxic psychosis. However, since memantine can induce
pharmacotoxic psychosis at doses that are only slightly effective,
glutamatergic activity in brain areas responsible for psychosis might
be reduced and further inhibited by the NMDA receptor
antagonist.
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Nausea and vasopressin
SIR,-A Lancet editorial has highlighted the intriguing relation
between vasopressin and a very poorly understood symptom,
nausea. Its summary of our work2 indicated that nausea and
increased vasopressin were not present in subjects with abnormal
gastric myoelectrical activity (gastric tachyarrhythmias) induced
during illusory self-motion. However, we did find gastric
arrhythmia present in those with nausea and increased vasopressin,
and our observations in fact support a potential gastric or vagal
mechanism that results in nausea and vasopressin secretion. By
altering vagal (or splanchnic) visceroceptive afferent nerve activity
projecting through the tractus solitarius to the hypothalamus,3.’ the
disruptive shift from normal gastric myoelectrical activity to
arrhythmia may be related to the stimulation of hypothalamic
vasopressinergic neurons and the release of vasopressin. Consistent
with this notion, a study of ipecacuanha showed that the early
gastric irritant phase of induced nausea was associated with
increases in plasma vasopressin. 5
An unresolved question in man remains whether or not nausea
releases vasopressin or release of vasopressin somehow contributes
to the sensation of nausea. The sequence of gastric
arrhythmia-+nausea-+vasopressin secretion (or vasopressin
secretion -+nausea) needs further investigation. The results of such
investigations may improve our understanding and treatment of
this noxious and very common symptom called nausea.
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Aspergillus antigen latex test for diagnosis
of invasive aspergillosis
SIR,-Invasive aspergillosis is a frequent infectious cause of
death in bone-marrow transplant recipients. Although the
detection of aspergillus antigen in serum, urine, or broncho-alveolar
lavage fluid can allow the rapid diagnosis of such infection/.3 the
lack of simple commercial tests has restricted the routine application
of this approach.
Over the past 15 months we have conducted a prospective
evaluation of a new latex agglutination test (’Pastorex Aspergillus’,
Diagnostics Pasteur) for the detection of circulating aspergillus
galactomannan. The latex used in this test is sensitised with a rat
IgM monoclonal antibody and can detect galactomannan at
concentrations as low as 15 ng/ml.
366 serum samples from 20 patients undergoing bone-marrow
transplantation were tested. Samples were collected at least three
times per week for 4 weeks or more after transplantation. 300 ul of
serum was mixed with 100 ul of edetic acid, heated to 100&deg;C for 3
min, then centrifuged at 10 000 g for 10 min. 20 ul of supernatant
was mixed with 5 III of sensitised latex on an agglutination card,
agitated at room temperature for 5 min, and the result read. The
control provided (Aspergillusfumigatus galactomannan antigen, 75
ng/ml) was included in all sets of tests and gave positive results
throughout.
13 patients (199 samples) had negative results on all occasions; 11 I
had no clinical, radiological, or microbiological findings suggestive
of aspergillus infection. In 1 patient a bronchoalveolar lavage (BAL)
specimen taken 7 weeks after transplant yielded A fumigatus; 16
serum samples taken during the first 10 weeks after transplant were
negative. In a second patient A fumigatus was recovered from
sputum taken 28 weeks after transplant; 23 serum samples taken up
to 34 weeks after transplant were negative.
